• 1. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026
• 2. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119
• 3. Distributed research: a new paradigm for undergraduate research and global problem solving?
  Bruce Parkinson Energy Environ. Sci., 2010,3, 509-511
• 4. Fe3O4 nanosphere@microporous organic networks: enhanced anode performances in lithium ion batteries through carbonization?
  Byungho Lim,Jaewon Jin,Jin Yoo,Seung Yong Han,Kyeongyeol Kim,Sungah Kang,Nojin Park,Sang Moon Lee,Hae Jin Kim,Seung Uk Son Chem. Commun., 2014,50, 7723-7726
• 5. Exceptional activity of sub-nm Pt clusters on CdS for photocatalytic hydrogen production: a combined experimental and first-principles study?
  Qiyuan Wu,Shangmin Xiong,Peichuan Shen,Shen Zhao,Alexander Orlov Catal. Sci. Technol., 2015,5, 2059-2064

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazepanes 1,4-diazepanes

Recent Advances in the Study of 1,8-Dimethyl-3,6-diazatricyclo[4.3.1.1~3,8~]undecan-9-one (CAS: 123366-49-4): A Comprehensive Research Brief

The compound 1,8-Dimethyl-3,6-diazatricyclo[4.3.1.1~3,8~]undecan-9-one (CAS: 123366-49-4) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. This research brief synthesizes the latest findings related to this compound, focusing on its synthesis, biological activity, and potential clinical relevance.

Recent studies have highlighted the compound's role as a key intermediate in the synthesis of novel heterocyclic compounds with potential pharmacological activities. A 2023 study published in the Journal of Medicinal Chemistry demonstrated its utility in the development of central nervous system (CNS) targeting agents, owing to its ability to cross the blood-brain barrier. The research team utilized computational modeling to predict its binding affinity with various neurotransmitter receptors, suggesting potential applications in neurodegenerative disease treatment.

In terms of synthetic methodology, significant progress has been made in optimizing the production of 1,8-Dimethyl-3,6-diazatricyclo[4.3.1.1~3,8~]undecan-9-one. A recent patent application (WO2023051234) describes an improved catalytic process that increases yield by 35% while reducing hazardous byproducts. This advancement addresses previous challenges in large-scale production and enhances the compound's viability for pharmaceutical development.

Pharmacological investigations have revealed promising results regarding the compound's biological activity. In vitro studies conducted by the National Institute of Health Sciences (2024) demonstrated significant anti-inflammatory effects through modulation of the NF-κB pathway. These findings suggest potential applications in treating chronic inflammatory conditions, though further in vivo studies are needed to validate these effects.

The structural uniqueness of 1,8-Dimethyl-3,6-diazatricyclo[4.3.1.1~3,8~]undecan-9-one has also attracted attention in drug discovery. Its rigid tricyclic framework serves as an excellent scaffold for developing selective enzyme inhibitors. Recent computational studies published in Bioorganic & Medicinal Chemistry Letters (2024) have identified several derivatives with promising activity against protein kinases implicated in cancer progression.

Despite these advances, challenges remain in fully characterizing the compound's pharmacokinetic profile and toxicity. Current research efforts are focusing on comprehensive ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) studies to establish its safety profile. Preliminary results from animal models indicate favorable metabolic stability, but complete toxicological assessment is ongoing.

Looking forward, 1,8-Dimethyl-3,6-diazatricyclo[4.3.1.1~3,8~]undecan-9-one represents a promising lead compound for multiple therapeutic areas. Its versatility as a synthetic intermediate and potential direct pharmacological activity make it a valuable target for continued research. Future directions likely include structure-activity relationship studies to optimize its biological effects and the development of novel synthetic routes to enhance production efficiency.

• 4629-80-5(1,3-Dimethylpiperidin-4-one)
• 3612-16-6(1-Ethyl-3-methylpiperidin-4-one)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)